ERBB2 and breast cancer: T-DXd was approved for use in the United States and the European Union in unresectable or metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic setting based on the DESTINY–Breast 01 trial [35].